Immunocore (NASDAQ:IMCR) Coverage Initiated by Analysts at Morgan Stanley

Morgan Stanley assumed coverage on shares of Immunocore (NASDAQ:IMCRGet Rating) in a research note released on Friday morning, MarketBeat.com reports. The firm issued an overweight rating and a $77.00 target price on the stock.

A number of other equities analysts have also recently issued reports on IMCR. Cowen began coverage on Immunocore in a report on Monday, August 8th. They set an outperform rating on the stock. BTIG Research began coverage on Immunocore in a report on Tuesday, August 2nd. They set a buy rating and a $85.00 price target on the stock. LADENBURG THALM/SH SH began coverage on Immunocore in a report on Thursday. They set a buy rating and a $82.00 price target on the stock. Cowen began coverage on Immunocore in a report on Monday, August 8th. They issued an outperform rating and a $70.00 target price on the stock. Finally, HC Wainwright reiterated a buy rating and issued a $80.00 target price on shares of Immunocore in a report on Tuesday, July 5th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of Buy and an average target price of $75.00.

Immunocore Price Performance

Immunocore stock opened at $44.75 on Friday. The stock has a market capitalization of $1.96 billion, a price-to-earnings ratio of -15.93 and a beta of -0.04. Immunocore has a 52-week low of $18.43 and a 52-week high of $61.32. The stock’s 50 day moving average price is $48.69 and its two-hundred day moving average price is $36.76. The company has a debt-to-equity ratio of 0.40, a quick ratio of 3.97 and a current ratio of 3.98.

Hedge Funds Weigh In On Immunocore

Several large investors have recently bought and sold shares of the stock. Rock Springs Capital Management LP lifted its stake in Immunocore by 3.3% during the 1st quarter. Rock Springs Capital Management LP now owns 2,552,034 shares of the company’s stock valued at $76,306,000 after acquiring an additional 80,479 shares in the last quarter. RTW Investments LP lifted its stake in Immunocore by 49.3% during the 1st quarter. RTW Investments LP now owns 1,859,471 shares of the company’s stock valued at $55,598,000 after acquiring an additional 613,939 shares in the last quarter. First Manhattan Co. lifted its stake in Immunocore by 58.6% during the 1st quarter. First Manhattan Co. now owns 808,549 shares of the company’s stock valued at $24,175,000 after acquiring an additional 298,693 shares in the last quarter. Paradigm Biocapital Advisors LP lifted its stake in Immunocore by 271.8% during the 1st quarter. Paradigm Biocapital Advisors LP now owns 499,190 shares of the company’s stock valued at $14,926,000 after acquiring an additional 364,941 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA lifted its stake in Immunocore by 2.8% during the 1st quarter. Massachusetts Financial Services Co. MA now owns 342,478 shares of the company’s stock valued at $10,240,000 after acquiring an additional 9,398 shares in the last quarter. 62.88% of the stock is currently owned by institutional investors.

Immunocore Company Profile

(Get Rating)

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers.

Further Reading

Analyst Recommendations for Immunocore (NASDAQ:IMCR)

Receive News & Ratings for Immunocore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunocore and related companies with MarketBeat.com's FREE daily email newsletter.